Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology • Medical Oncology • Her2+ • HR+ • Breast Cancer, Metastatic • Breast Cancer, Non-metastatic • tnbc • HER2-low • ESMO 2024
What are your top takeaways in Breast Cancer from ESMO 2024?
Answer from: Medical Oncologist at Academic Institution
The most interesting and impactful paper was LBA18 – DESTINY-Breast12 showing significant responses in HER2+ brain metastases – including untreated brain metastases. The median PFS and survivals were truly impressive Abstract 3400, testing patritumab (HER3-targeting antibody-drug co...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
In the early BC area, I thought 3 abstracts were of major importance.
KN522 overall survival advantage for neoadjuvant/adjuvant pembrolizumab together with NACT. This strengthens the argument that patients meeting the KN522 eligibility criteria should receive preoperative therapy with IO, and not g...
Answer from: Medical Oncologist at Academic Institution
KEYNOTE-522
DESTINY-Breast12
NATALEE
Answer from: Medical Oncologist at Community Practice
NATALEE Trial (ER-positive/HER2-negative breast cancer): The NATALEE phase 3 trial tested ribociclib in the adjuvant setting alongside an aromatase inhibitor for stage 2 and 3 ER-positive/HER2-negative breast cancer. After four years, there was a nearly 5% improvement in invasive disease-free...